CJC-1295 and Ipamorelin are two peptides frequently studied together in growth-hormone-axis research. This article provides an educational overview of what the published scientific literature reports about each peptide, their individual mechanisms, and why they are commonly examined as a pair. All information below is provided strictly for research and informational purposes.
What are CJC-1295 and Ipamorelin?
Both belong to a research class known as growth-hormone secretagogues — compounds studied for their interaction with the body's own growth-hormone signalling pathways, rather than introducing growth hormone directly.
- CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), based on the GHRH (1-29) sequence. Research describes it as interacting with GHRH receptors on the pituitary. It exists in forms with and without a "DAC" (drug affinity complex) modification, which research associates with differing durations of activity.
- Ipamorelin is a selective pentapeptide that research describes as acting on the growth-hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor — a different pathway to CJC-1295.
Both are typically supplied as lyophilised powders for research use.
Why they are studied together
The scientific interest in the pairing comes from the fact that the two peptides act on two distinct receptor pathways. The published literature describes CJC-1295 as associated with a more sustained signalling pattern, and Ipamorelin with a more immediate, pulsatile pattern. Researchers study the combination as a model for how these complementary pathways interact within the growth-hormone axis. Literature also notes that Ipamorelin attracted research interest for its reported selectivity — producing growth-hormone-axis activity in studies with comparatively little effect on other pathways such as cortisol, compared with some earlier compounds in its class.
What the research has reported
Individual published studies have examined each peptide's effect on growth-hormone-axis markers in research and clinical settings. The combination is frequently discussed in the research literature as a mechanistic model for dual-pathway growth-hormone-axis stimulation. As with many peptides in this category, researchers note that comprehensive large-scale human clinical data is limited, and much characterisation is mechanistic.
Regulatory status in Australia
Neither CJC-1295 nor Ipamorelin is approved by the Therapeutic Goods Administration (TGA), and neither is listed on the Australian Register of Therapeutic Goods (ARTG) for therapeutic use. They are supplied strictly as research compounds.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. CJC-1295 and Ipamorelin are supplied strictly as research compounds, for in-vitro laboratory research use only. They are not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.